The FDA's loudest critics on the safety issue have changed how FDA works-particularly in its far more public sharing of risk information. In a series of four interviews with FDA experts we explore the implications of these and other changes to the FDA's approach to safety. But one summary point: instead of trying to defend its record against an ever-increasing safety standard, the FDA--and some companies, too--are trying to teach consumers that all drugs have risks by informing them directly and frequently and thereby inoculate them against the more extreme requirements of the product-safety lobby.
By Roger Longman
The Food & Drug Administration has always had critics on each side of the risk-benefit divide—those who are most concerned...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.
Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.
An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.
Flagship Pioneering senior partner Raj Panjabi discusses shifting health care from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.
Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.
